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Abstract
Purpose: The objectives of the study were: (1) to determine kanamycin plasma concentrations using liquid 
chromatography coupled with mass spectrometry (LC-MS), (2) to investigate kanamycin pharmacokinetics (PK) in 
patients with multi-drug resistant tuberculosis (MDR-TB), (3) to find out whether HIV infection, kidney dysfunction and 
antiretroviral drugs influence kanamycin PK.
Methods: The study was designed as a non-randomized study involving male and female HIV- positive and HIV-
negative patients admitted for MDR-TB treatment. Blood samples were collected before (baseline) and ½, 1, 2, 4, 8 and 
24 hours after intramuscular injection of kanamycin. LC-MS was used to quantify kanamycin plasma concentrations.
Results: Thirty one patients including 13 HIV (+) participated in the study. The lower limit of detection and lower 
limit of quantification of kanamycin were 0.06 µg/ml and 0.15 µg/ml respectively. Kanamycin PK parameters were 
described and there was no significant difference between HIV-positive and HIV-negative patients. A statistical significant 
difference (p=0.0126) was found in the renal function in HIV - positive and HIV - negative patients. However, this 
difference did not affect kanamycin elimination. No interactions have been identified between antiretroviral drugs and 
kanamycin. Conclusion: LC-MS analysis method is highly specific and highly sensitive in the detection and quantification 
of kanamycin plasma concentrations. Kanamycin PK in patients with MDR-TB was described. Due to a limited number 
of patients, we cannot rule out any influence of HIV - infection, renal impairment and antiretroviral drugs on kanamycin 
pharmacokinetics. The relationship between the area under the curve of kanamycin free plasma concentrations (fAUC) 
and its minimum inhibitory concentrations (MIC) on M.tuberculosis isolated from the sputum of each patient should be 
assessed. Therefore, kanamycin free plasma concentrations and MIC should be determined
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Introduction
The surge of multidrug- resistant tuberculosis (MDR-TB) is raising 
concerns globally and in sub-Saharan Africa [1-6]. Although the 
epidemiological relationship between HIV infection and MDR-TB has 
not been established in sub- Saharan Africa [7-10], clinical evidence has 
shown that there is a link between HIV infection and the development 
of MDR-TB [11-14]. 
Many studies have confirmed that HIV -positive patients do not 
adequately absorb anti-TB drugs resulting in sub-therapeutic outcomes 
of anti-TB therapy that may result in the development of resistance to 
anti-TB drugs [12,13,15]. This evidence has not yet been confirmed for 
many of the second-line anti-TB drugs. 
Interactions between anti-retroviral drugs and anti-TB drugs alter 
the plasma concentrations of anti-TB drugs and these interactions 
could result in sub-therapeutic anti-TB drugs plasma concentrations. 
For first-line anti-TB drugs, major drug/drug interactions occur 
between rifampicin (RIF) and highly active anti-retroviral therapy 
(HAART) drugs, protease inhibitors (PIs) and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) [16, 17]. Furthermore, interaction 
between tenofovir and kanamycin as a result of reduced elimination 
by the kidney could result in an increase in the plasma concentration 
of kanamycin. 
Consequently, a better understanding of the pharmacokinetics 
(PK) and pharmacodynamics (PD) of anti-TB drugs should improve 
treatment outcomes in patients with MDR-TB infection and in patients 
with MDR-TB co-infected with HIV [18]. 
Kanamycin is one of the drugs used in the intensive phase treatment 
of MDR-TB. The PK of kanamycin has been studied in healthy 
volunteers using microbiological assay methods and to a limited 
extent in patients with MDR-TB [19,20]. To the best of our knowledge, 
there is no recently published study on the analysis of kanamycin 
plasma concentrations using liquid chromatography coupled with 
mass spectrometry (LC-MS). In addition, little information exists on 
the PK of kanamycin in HIV -negative patients infected with MDR-
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TB [21], and currently there is no information on its PK in South 
African patients with MDR-TB infection and in patients with MDR-
TB co-infected with HIV [22]. Therefore, information obtained from 
this study might help for future development of therapeutic drug 
monitoring (TDM) in order to improve patients’ treatment outcome 
and optimise drug therapy. 
Hence, we determined kanamycin plasma concentrations using 
LC-MS and evaluated the PK of kanamycin in patients with MDR-
TB and in patients with MDR-TB co-infected with HIV during their 
course of treatment. We also examined the influence of HIV infection 
on kanamycin PK. We evaluated the effect of the kidney dysfunction 
on kanamycin PK and assessed the interaction between antiretroviral 
drugs and kanamycin.
Methods
Study site, design and subjects
The study was conducted at Brewelskloof Hospital (BKH), South 
Africa. BKH is one of the South African hospitals specialized in the 
treatment of MDR-TB. The study was designed as a prospective, non 
randomized pharmacokinetic study involving male and female HIV- 
positive and HIV-negative patients admitted for MDR-TB treatment.
Inclusion and exclusion criteria 
A patient was included in the study if he/she complied with all of 
the following: (1) Signature of informed written consent; (2) Informed 
consent for HIV test; (3) On kanamycin treatment for at least 2 weeks; 
(4) Adult patients 18 - 65 years old; (5) MDR-TB sensitive to second - 
line anti-TB drugs. 
Patients were excluded from the study in case any of the following 
criteria applied: (1) Patient request; (2) History of congestive cardiac 
failure; (3) Uncontrolled hypertension; (4) Ischemic heart disease; (5) 
Pregnancy or breast feeding; (6) Hypersensitivity to kanamycin; (7) 
Patients on drugs other than anti-retroviral drugs, known to interact 
with kanamycin; (8) Older than 65 years and younger than 18 years; (9) 
Haemoglobin less than 10g%, and (10) severe dehydration.
Kanamycin dose and blood sampling 
Patients received kanamycin at a dose of 500, 600, 660, 750, 1000 
mg daily based on their body weight. On the study day, after an 8-hour 
overnight fast, blood samples were collected in a heparinised tube via 
an intravenous catheter fixed on the forearm vein before (baseline) 
and ½, 1, 2, 4, 8 and 24 hours after intramuscular administration of 
kanamycin. Blood samples were immediately centrifuged at 5,250 rpm 
for 5 minutes. Then, plasma was separated and stored at -80ºC until the 
day of analysis. Blood was also collected for renal and liver function 
tests, CD4 counts, viral load and haematology tests.
Determination of kanamycin plasma concentrations and 
chemicals used
Plasma levels of kanamycin were determined using LC-MS. The 
following chemicals were used in the study: analytical grade dimethyl 
sulfoxide (DMSO), acetonitrile (ACN), trichloroacetic acid (TCA), 
phosphoric acid and HPLC grade trifluroacetic acid (TFA). All of 
them were obtained from Sigma-Aldrich (Cape Town, Western Cape). 
Kanamycin was supplied by BKH and used as a working standard. 
Liquid Chromatography-Mass Spectrometry 
LC-MS was performed with Waters Acquity UPLC system 
connected to a Xevo triple quadrupole mass spectrometer (Waters, 
Milford, MA, USA). The Waters Atlantis is a reversed phase packing 
with a difunctional C18 ligand, designed to retain polar compounds 
better. The mobile phase used was 1 % formic acid in water (v/v) as 
solvent A, solvent B consisted of acetonitrile. A flow rate of 0.23 ml/
min was applied and an injection volume of 5 µl. The gradient started 
at 98% solvent A for the first 2 minutes followed by a linear gradient 
over 8 minutes to 70 % solvent B. The column was washed for 1 minute 
at 100% solvent B and re-equilibrated for another 6 minutes at the 
starting conditions.
The MS conditions were as follows: electrospray ionization in the 
positive mode was applied, the ion source and desolvation temperature 
were held at 140 ºC and 400 ºC, respectively. The capillary voltage was 
2.8 kV. The desolvation gas at 1000 L/h and the cone gas was 50 L/h. 
The instrument was operated at multiple reactions monitoring (MRM) 
mode. The MRM settings for kanamycin was 485 > 163 at collision 
energy 20 eV.and cone voltage of 20 V. Propanolol was used as internal 
standard and was monitored at an MRM of 260.3 >183 at a collision 
energy of 20eV and cone voltage of 18 V. Waters MassLynx™ software 
was used for the data collection and processing. 
Preparation of standards
The stock solution of 1 mg/ml was serially diluted with acetonitrile 
to obtain working solutions with the concentrations 10, 5, 1, 0.5, 0.1, 
0.05 and 0.01µg/ml. All these standards contained 10 ppm propanolol 
as internal standard.
Patient samples preparation
To prepare the patients’ plasma samples for the LC-MS assay, 
trichloroacetic acid (30 µl) was added to 50 µl plasma followed by 
170 µl internal standard solution (10 ppm propanolol in water). The 
mixture was vortexed for 1 minute, followed by centrifugation at 
6000 g for 5 minutes. The supernatant was injected onto the LC-MS. 
Blank plasma was spiked with 1 and 5 ppm of kanamycin in triplicate 
to determine the recoveries and repeatability. The relative standard 
deviation was better than 12%. This relatively high standard deviation 
and relatively high limit of detection and quantification is due to the 
fact that kanamycin elutes just after the void volume of the column. 
The use of a C18 column with similar selectivity as the Waters Atlantis 
column used here is very important for this analysis.
Determination of pharmacokinetic parameters
The plasma concentration-time profile for each patient was 
plotted using a semi-log graph paper. Kanamycin PK parameters 
were calculated based on the non-compartmental analysis [22-24] and 
expressed as median and range (lowest to highest).
Statistical analysis
Patients’ data were organised and coded onto data collection 
forms and captured into Microsoft Excel spreadsheets. Kanamycin 
concentrations and PK parameters were analysed using descriptive 
statistics. Analysis was done using SAS version 9.0 (SAS Institute Inc., 
Cary, NC, USA).
Since the data is highly skewed in many cases, the HIV+ and HIV- 
groups were compared using the Wilcoxon Rank Sum test rather 
than a t-test. PK parameters were reported as mean and standard 
deviation. The Kruskal-Wallis one-way analysis of variance was used in 
comparing more than two groups to see if they originate from the same 
population. Statistical significance was assumed at the p < 0.01 level to 
avoid a type 1 error (false positive).
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The number of patients in HIV-positive and HIV-negative groups 
was sufficient to give a power of about 80% in detecting a statistical 
significant difference in the means of about 1.2 standard deviations 
based on our power calculations. Also, the number of patients who 
participated in previously published studies [21,25-28] was similar to 
the number of patients in our study. 
Ethics consideration
The study was approved by the ethics committee of the University 
of the Western Cape and the University of Cape Town. Permission to 
conduct the study was granted by the Western Cape Department of 
Health. It was conducted according to the national and international 
ethics requirements. The information collected was kept confidential 
and saved in a safe file which can only be accessed by the researcher. 
Patient confidentiality and privacy was maintained at all times.
Results
Patients’ demographic data 
Thirty-one patients (17 males and 14 females) infected with MDR-
TB participated in the study. Of these 31 patients, 13 (8 males and 5 
females) were infected with HIV. The median (range) age and weight 
of patients were 32 (18–54) years and 53.0 (41.8–90.0) kg, respectively.
Renal and liver function profile
The renal function was normal in 5 HIV (+) and 15 HIV (-) 
patients, mildly impaired (60-89 GFR) in 6 HIV (+) and 3 HIV (-) 
patients, moderately impaired (40-59 GFR) in 2 HIV (+) patients. Liver 
function tests were normal in both HIV (+) and HIV (-) patients.
Virological profile
In HIV (+) patients the CD4 count (cells/mm3) was <100 in 5 
patients, 100-299 in 3 patients and > 300 in 5 patients. The viral load 
was less than 40 copies/ml in 10 patients and 5,000 to 1,000,000 copies/
ml in 3patients. 
Validation of the method of kanamycin liquid 
chromatography-mass spectrometry analysis 
Liquid chromatography coupled with mass spectrometry was 
used in the quantification of kanamycin plasma concentrations. This 
method was validated by determining linearity, recovery, precision 
and accuracy, low limit of detection, low limit of quantification, and 
specificity.
The overall precision expressed as relative standard deviation (RSD 
%), was less than 12%. The accuracy, expressed in terms of recovery was 
74 ± 9.1% and 111 ± 6.2% for 1 µg/ml and 5 µg/ml, respectively. 
The lower limit of detection of kanamycin was 0.06 µg/ml. The 
lower limit of quantification of kanamycin in the plasma was 0.15 µg/
ml.
There were no interfering peaks from the plasma components with 
kanamycin peak in the blank plasma, which was detected at a retention 
time of 2.65 minutes. Figure 1 shows the chromatograms of kanamycin 
and internal standard of a patient’s plasma. This relatively high standard 
deviation and relatively high limit of detection and quantitation is 
due to the fact that kanamycin elutes just after the void volume of the 
column. The use of a very polar C18 column is very important for this 
analysis as most other columns and solvent systems tested were unable 
to retain kanamycin.
Kanamycin pharmacokinetic parameters 
Table 1 and Figure 2 present kanamycin mean plasma concentrations 
in HIV-negative and HIV-positive patients at different times of blood 
sampling as indicated in the methods. The standard deviations (STD) 
and P-values between HIV-negative and HIV–positive are also shown. 
Before kanamycin administration there were no detectable plasma 
concentrations from previous day kanamycin administration in both 
HIV - positive and HIV - negative patients. However, 24 hours after 
current study kanamycin dosing, the mean plasma concentrations we 
1.27 ± 2.89 µg/ml in HIV (+) and 0.97 ± 2.54 µg/ml in HIV (-) patients.
Table 2 and Figures 3-5 present kanamycin pharmacokinetic 
parameters in HIV-negative and HIV-positive patients. The 
elimination rate constant (Ke), the elimination half-life (T1/2), the area 
under the plasma concentration curve during 24 hours (AUC0-24), 
the area under the plasma concentration curve from zero to infinity 
(AUC0-∞), the maximum plasma concentrations (Cmax), the time to the 
maximum plasma concentrations (Tmax), the absorption rate constant 
(ka), the absorption half-life (t1/2), the volume of distribution (Vd), the 
total clearance (Cltot), and the mean residence time (MRT) are given in 
Table 2 in the order at which they appear. Each parameter is shown as 
mean value plus STD. P-values between HIV (-) and HIV (+) patients 
are also indicated.
Discussion
Determination of kanamycin plasma concentrations using 
liquid chromatography-mass spectrometry
The LC-MS method is a proven method and has been widely used 
in the quantification of anti-TB drugs [22-24]. The plasma levels of 
kanamycin were determined using LC-MS method and analysis was 
conducted according to scientific standards. The linearity, lowest 
limit of detection, lowest limit of quantification, specificity, precision, 
recovery and accuracy were conducted to validate the assay. All 
chemicals used were prepared and standardised regularly. Chemicals 
were obtained from a reputable source (Sigma-Aldrich, Cape Town). 
Separation of kanamycin was achieved at a retention time of 1.50 
minutes with a high recovery percentage of 92.5%.
Previously published studies have used microbiological and 
fluoroimmunoassay in the quantification of kanamycin [21,25-28]. 
This study results demonstrate that the LC-MS analysis method is 
highly successful and accurate in the detection and quantification of 
kanamycin concentrations in plasma.
At baseline kanamycin plasma concentrations were below 
detectable levels (0.05 µg/ml). This could be as a result of an insufficient 
amount of kanamycin remaining in the body 24hrs after previous 
dosing that could be detected at baseline. 
Kanamycin pharmacokinetics
Kanamycin PK parameters have been described in 3 studies in 
healthy volunteers [25,26,28] and in one study involving HIV -negative 
patients infected with MDR-TB [21] using immunoassay methods. 
Cmax , Tmax , Ke , T1/2 , Cltot and Vd results of these studies range from 20 
to 35 µg/ml, 1 to 2 hours, 0.29 to 0.30 hr-1, 2 to 4 hours, 5 to 6 L/hr and 
17–23 L respectively [21,25,26,28].
When comparing kanamycin PK parameters in previous studies to 
that of HIV -negative patients in the study, the mean Cmax (18.39 µg/
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ml) was lower, Tmax (1hr) was similar, Ke (0.13hr-1) was lower, T1/2 (5.37 
hrs) was longer, Cltot (4.00L/hr) was higher and Vd (33.02L) was higher. 
The increased Vd kanamycin could be responsible for the long time 
kanamycin molecules resided in HIV-negative patients [20,25,26,28].
Influence of human immunodeficiency virus on the 
pharmacokinetics of kanamycin 
The rate and extent of absorption of kanamycin as represented by 
the Tmax and Cmax were similar in both HIV -positive and HIV -negative 
patients. The AUC0-24, which quantifies the extent of absorption of 
kanamycin was also similar in HIV -positive and HIV -negative patients. 
HIV -positive patients were not severely affected by HIV. Many HIV 
positive patients had good immunological and virological profile. Eight 
out of thirteen patients had a CD4 count within the ranges of (100-599) 
cells/mm3 and ten had a viral load of less than 40 copies/ml. 
When compared to other HIV -positive patients in the study, a 
reduction in the extent of distribution of kanamycin in two patients 
with CD4 count of 382 and 336 cells/mm3 and represented by a Vd 
of 13.28 and 15.39 L, respectively, might be associated with the short 
elimination T1/2 of 2.10 and 3.15 hours and MRT of 2.39 and 2.87 hrs, 
respectively that was observed. The T1/2 of a drug is a PK parameter 
dependent on both Vd and CLtot and is a reflection of the extent of the 
distribution or elimination of a drug [29-32]. Similarly, an increase in 
the Vd (60.22, 51.92, 26.26 and 30.17 L) of kanamycin in some patients 
as compared to other HIV -positive patients resulted in the lengthening 
of the elimination T1/2 of 6.30, 8.77, 11.00 and 5.33 hrs and MRT of 7.92, 
8.80, 12.96 and 4.69 hrs, respectively.
There were no significant differences in the PK parameters of 
kanamycin in HIV -positive patients when compared to the mean PK 
parameters in HIV -negative patients. The smallest observed p-value 
is about 0.48 However, it should be remembered that the sample sizes 
are relatively small so that there is limited power to detect differences. 
Differences may in fact exist but could not be detected statistically.
Influence of renal dysfunction on the pharmacokinetics of 
kanamycin: 
There was a significant difference (p=0.013) in the renal function 
between the HIV -positive and HIV -negative patients. However 
there was no significant difference (p=0.31) when we correlated the 
GFR values and the PK parameters in the two groups of patients to 
see if changes in the renal function affected the PK of kanamycin. 
HIV could be responsible for the significant difference in the renal 
function between HIV -positive and HIV -negative patients. A decline 
in renal function and low CD4 count are associated with HIV-related 
nephropathy, due to HIV infecting the renal cells directly [33-35]. Also, 
we had more patients with impaired renal function in the HIV -positive 
group than in the HIV -negative group and this could have contributed 
to the statistical difference. This result is consistent with a study done 
in South African patients, reporting that HIV-related nephropathy is 
exhibited in HIV positive patients at any stage of HIV infection and is 
characterised with varying degrees of GFR [33].
   
Time
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%
0
100
1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00 11.00 12.00 13.00 14.00
%
0
100
PM_UWC_120825_7 MRM of 11 Channels ES+ 
260.2 > 183 (propranolol)
1.06e7
7.39
PM_UWC_120825_7 MRM of 11 Channels ES+ 
485 > 163 (kanamycin)
2.07e6
2.65
 
Figure 1: MRM chromatograms of patient plasma, showing the internal standard on top and kanamycin at the bottom.
Time HIV - NEG   (N=18) HIV - POS   (N=13) P-value
(hr) Mean (µg/ml) STD Mean (µg/ml) STD
t0 0.00 0 0.00 0 1
t0.5 1.94 3.83 3.83 5.27 0.3472
t1 16.43 5.63 15.94 7.47 0.9447
t2 14.33 5.92 14.46 4.78 0.9916
t4 9.06 3.79 9.83 3.18 0.7004
t8 4.96 4.13 5.64 4.14 0.4105
t24 0.97 2.54 1.27 2.89 0.5139
Table 1: Kanamycin plasma concentrations in HIV-negative and HIV-positive patients.
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Influence of antiretroviral drugs on the pharmacokinetics of 
kanamycin?
Kanamycin was administered with other MDR-TB drugs to all 
patients. Some of the HIV positive patients were also given lamivudine, 
stavudine and efavirenz. None of these drugs affected the metabolism, 
distribution and renal elimination of kanamycin. 
Therapeutic implications
The two common PK parameters associated with the clinical 
efficacy of aminoglycosides are Cmax and AUC0-24 [36]. High peak 
plasma concentration of aminoglycosides is associated with increased 
rate of elimination of Mycobacterium tuberculosis (MTB) and better 
therapeutic response in patients [4,12]. However, due to the narrow 
therapeutic range (20-35) µg/ml of aminoglycosides [12], care must 
be taken when administering kanamycin in patients with renal 
impairment. 
Kanamycin shows inhibitory activity against MTB at concentration 
of about 6 µg/ml in vitro and an intramuscular dose of 15 mg/kg 
produces a Cmax of 35-45 µg/ml [4,12]. Most of our patients had a 
low peak plasma concentration of kanamycin when compared to 
the literature [25-28]. A median dose of 18.9 mg/kg of kanamycin in 
both HIV -positive and HIV –negative patients in the study resulted 
in a peak plasma level of 18.19 (8.40-27.63) µg/ml and 18.39 (13.32-
25.26) µg/ml, respectively. The low Cmax could result in poor response 
to therapy and increased risk of selection of drug-resistant organisms. 
This is because kanamycin has a concentration-dependent bactericidal 
activity as the rate of bacterial killing increases as the concentration 
increases [37-40]. In addition, the Cmax: MIC ratio correlates best with 
bacterial killing and it is important to have a high Cmax: MIC ratio of at 
least 8–10 to prevent resistance for aminoglycosides [40,41]. Therefore, 
the ideal dosing regimen of kanamycin would maximise concentration, 
because the higher the concentration, the higher the extent of bacterial 
killing [40]. 
It has been suggested that clinicians should aim for a Cmax of 
between 20 and 35 µg/ml to maximise the rate and extent of bacterial 
killing and a Ctrough (trough level) of <10 µg/ml to prevent toxicity 
when kanamycin is given intramuscularly [12]. Based on our results, 
the mean Ctrough of kanamycin in HIV -positive and in HIV -negative 
patients was 1.27 ± 2.89 µg/ml and 0.97 ± 2.54 µg/ml respectively. This 
explains that kanamycin plasma levels were not toxic in our patients.
Furthermore, a high Cmax: MIC ratio suggests a persistent prolonged 
period of bacterial growth inhibition after exposure to aminoglycosides. 
Clinically, the post antibiotic effect (PAE) for aminoglycosides is 
usually between 2 and 4 hours [42]. The PAE of aminoglycosides 
suppresses bacterial regrowth when serum concentrations are below 
the MIC [42,43].
Limitations of the Study
We had an unequal distribution of patients in the HIV-positive and 
HIV-negative groups. Thirty-one patients volunteered to participate in 
the study, of which 13 were HIV-positive. Also, there were very few 
patients with kidney dysfunction and no drug–drug interaction was 
observed between kanamycin and co-administered medications. 
There was no balance in the CD4 count and viral load in HIV-
positive patients. Five patients had a CD4 count of <100 cells/mm3 and 
eight had a CD4 count of >100 cells/mm3. Some patients were in the 
early stage of the disease, while some had advanced HIV infection. In 
addition, studies on the PK of kanamycin are very scarce, especially in 
sub-Saharan Africa. Thus, comparison of our results with previously 
published studies for similarities or differences in the PK parameters 
was limited. Future studies involving more volunteers are needed.
   
Figure 2: Kanamycin Mean Plasma Concentration over Time
PK HIV - NEG   (N=18) HIV - POS   (N=13) P-value
Parameters Mean (µg/ml) STD Mean (µg/ml) STD
Ke (hr
-1) 0.20 0.11 0.19 0.08 0.8205
Tmax (hr) 1.16 0.49 1.27 0.53 0.6159
Ka (hr
-1) 1.29 1.32 1.05 0.88 0.8357
t1/2 (hr) 1.67 1.86 1.29 1.59 0.9273
T1/2 (hr) 4.45 2.25 4.62 2.66 0.8205
Cltot (L/hr) 7.72 5.49 9.13 8.93 0.7153
MRT (hr) 3.99 3.01 4.16 3.56 0.7674
Cmax (µg/ml) 18 4.69 16.35 5.76 0.4892
Vd (L) 38.62 18.56 50.18 45.34 0.7078
AUC0-24 (µg/ml.hr) 122.53 58.58 122.89 77.94 0.6217
AUC0-∞ (µg/ml.hr) 170.26 91.37 169.08 115.32 0.5669
Table 2: Kanamycin PK parameters in HIV-negative andHIVpositive patients.
   
Figure 3: Kanamycin Pharmacokinetic Parameters (1)
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Conclusion
Based on the results obtained, we can conclude that objectives of 
the present study were achieved.
The LC-MS analysis method is highly specific and highly sensitive 
in the detection and quantification of the plasma concentrations of 
kanamycin. The PK of kanamycin in patients with MDR-TB and in those 
with MDR-TB co-infected with HIV was described. Furthermore, HIV 
infection does not have any influence on the PK of kanamycin. Finally, 
changes in renal function do not influence the PK of kanamycin. 
Recommendations 
Based on the results of this study, the following should be 
considered for future studies.
Kanamycin-free plasma concentrations should be evaluated, in 
order to determine the AUC of the free plasma concentrations (fAUC) 
which, together with the MIC will be used to determine the relationship 
between fAUC and MIC of kanamycin. 
Therefore, the MIC of kanamycin on M.tuberculosis isolated from 
the sputum of each patient should be determined. 
 PK/PD relationship of kanamycin should be determined, because 
it quantifies the activity of an antibiotic and describes the time course 
of action of the antibiotic.
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